Roche Licenses Hanmi’s Muscle-Sparing Obesity Drug
August 25, 2026
Roche’s Genentech will pay $190 million upfront for global rights to Hanmi’s experimental obesity drug HM17321.
August 25, 2026
Roche’s Genentech will pay $190 million upfront for global rights to Hanmi’s experimental obesity drug HM17321.